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ABSTRACT
Traditionally, Clinacanthus nutans (CN) or locally named as ‘Belalai Gajah’ is one of the herbal plant claimed to be 
able to treat cancer. The aimd of this study are to extract, isolate and characterize the active anticancer compound 
from CN and to determine the mode of cell death induced by the compound. Bioassay guided fractionation was done on 
the CN extract by using column chromatography. The cytotoxicity activities of these fractions toward HeLA cells were 
examined by MTT assay. The nuclear morphology was examined by Hoechst 33258 staining and the cell cycle arrest 
was evaluated by propium iodide staining using flow cytometry. The presence of active compound in the chosen fraction 
was determined by Liquid Chromatography Mass Spectrometry (LCMS). Out of 16 fractions collected, Fraction 11(F11) 
showed the lowest IC50 value with 27 ± 2.6 µg/mL. The value of IC50  for F11 towards normal cell, NIH 3T3 cell and L929 
cell, were 70 ± 4.0 µg/mL and 45 ± 1.5 µg/mL respectively. These values were higher than tamoxifen, therefore indicating 
that tamoxifen is more toxic towards normal cells compared to F11. Nuclear morphology of HeLA cell displayed DNA 
fragmentation, nuclear condensation and formation of apoptotic bodies upon treatment with F11 for 24 hours. The cell 
cycle distribution of HeLA cell treated with F11 was arrested at G1 phase. The active compound identified to potentially 
possess the anticancer property is 19-Oxo-all-trans-retinoic acid. In conclusion, 19-Oxo-all-trans-retinoic acids from 
F11 of the CN extract, is a potential anticancer agent for cervical cancer.
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ABSTRAK
Secara tradisi,  Clinacanthus nutans (CN) atau dikenali sebagai ‘belalai gajah’ adalah salah satu tumbuhan herba 
yang dipercayai boleh merawat penyakit kanser. Tujuan kajian ini adalah untuk memencilkan dan mencirikan sebatian 
antikanser yang aktif dari CN dan menentukan cara kematian sel yang disebabkan oleh sebatian ini. Penfraksian 
berpandukan bioaktiviti telah dilakukan dengan menggunakan kromatografi turus. Aktiviti sitotoksisiti untuk kesemua 
fraksi terhadap sel HeLA telah diuji oleh asai MTT.  Morfologi nuklear telah ditentukan dengan menggunakan pewarna 
Hoechst 33258 dan penghalangan kitaran sel telah dinilai oleh analisis flowsitometri. Sebatian aktif yang terdapat dalam 
fraksi yang dikehendaki telah diuraikan dengan menggunakan Kromatografi Cecair Spektometri Jisim (LCMS). Fraksi 11 
(F11) daripada 16 keseluruhan fraksi yang terkumpul merekodkan nilai IC50 paling rendah iaitu 27 ± 2.6 µg/mL. Apabila 
F11 diuji terhadap sel yang normal, nilai IC50 untuk F11 terhadap sel L929 adalah 45 ± 1.5 µg/mL manakala terhadap 
NIH 3T3 adalah 70 ± 4.0 µg/mL. Nilai-nilai ini adalah lebih tinggi berbanding sel yang dirawat dengan tamoxifen. Hal 
ini menunjukkan bahawa tamoxifen adalah lebih toksik terhadap sel normal berbanding dengan F11. Morphologi sel 
HeLA menunjukkan kondensasi DNA, fragmentasi nukleus dan pembentukan badan apoptotik apabila dirawat dengan 
F11 untuk tempoh 24 jam. Perkembangan kitaran sel HeLA yang dirawat dengan F11 menunjukkan kitaran sel terhenti 
di fasa G1. Sebatian antikanser aktif yang dipercayai mempunyai ciri-ciri antikanser adalah asid retinoik semua-trans-
oxo-19. Kesimpulannya, F11 mengandungi sebatian antikanser,  asid retinoik semua-trans-oxo-19, yang berpotensi untuk 
dibangunkan sebagai agen untuk anti kanser rahim.
Kata kunci: Clinacanthus nutans; pencirian; kanser pangkal rahim; apoptosis; sitotoksisiti
INTRODUCTION
Throughout the ages, human have relied on nature to 
fulfill their basic needs especially for the production of 
foods and medicines. The use of herbal as alternative 
medicines has become increasingly popular in Malaysia 
and also throughout the world. One of the reasons why 
people turn to alternative herbal therapies is because of 
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the failure of some conventional medical approaches to 
produce positive treatment results. In addition, herbal 
medicines are perceived by the public to have lesser side 
effects as compared to allopathic medicine. Combination 
of both traditional genetic approaches and the new wealth 
of genomic information have led to promising strategies 
in utilizing drugs profile to target tumor cells death in 
molecular context. Similarly, it may be possible to identify 
and validate new targets for drugs that would selectively 
kill tumor cells with a particular molecular context.
Cancer disease is a serious and major problem 
worldwide. The main cause of cancer is still to be 
determined. However, diet, chemicals, life style, family 
history, bacteria and viruses are important causes toward 
the formation of cancer (Alwahaibi & Mohamed 2008). 
Cancer is known to bring bad effects in human and in 
many cases, it would be fatal. In current world scenario, 
most patients diagnosed with cancer will depend on 
chemotherapy drugs to eradicate the cancer cells even 
though chemotherapy is known to have severe side effects 
on the patients. Hence, nowadays, people are focusing on 
producing herbal medicine since it is safer and is easily 
marketable in the society. Clinacanthus nutans (CN) was 
used in this study to examine the anticancer properties 
of its compound towards HeLA cell. In Malaysia, this 
plant is popular in Sabah and is known as snake plant 
or locally named as ‘belalai gajah’. Traditionally, CN is 
used as an anti-inflammatory and also for skin rashes 
(Janwitayanuchit et al. 2003; Sangkitporn et al. 1995). 
Clinacanthus nutans (Burm. F.) Lindau and Clinacanthus 
siamensis Bremek are often being mistaken with each 
other since these two species have similar morphology 
in botanical viewpoint. However, these two species are 
actually different in term of their molecular aspects and 
pharmacological characteristics (Kunsorn et al. 2013). 
Apparently, these two plants are available in the market 
in different forms of preparation such as lotion, herbal tea, 
cream, capsule and concentrated extract. However, due to 
limited information on their pharmacological properties, 
most of their products do not gain much popularity among 
users (Alam et al. 2016). Currently, these plants have 
attracted many researchers to study their medical potential. 
According to the locals in Sabah, patients with stage 
three cancers that were not undergoing chemotheraphy 
treatment, showed improvement after consuming CN. 
Previous study showed that CN extract inhibited cancer 
cell proliferation and is potent against cervical cancer cell 
line, HeLA. (Yong et al. 2013). However, the compound 
responsible for this anticancer effect is not yet elucidated. 
Hence, the aims of this study are to extract and isolate the 
active anticancer compound from CN and to examine the 
cytotoxic effects towards cancerous cell line, HeLA cell. 
Fraction that showed the most potent activity towards the 
cell line was selected for further study to determine the 
mode of cell death induced and for characterization of the 
active compound.
MATERIALS AND METHODS
PLANT SAMPLING AND EXTRACTION
Leaves of Clinacanthus nutans (CN) were collected from 
Pengkalan Chepa, Kelantan, Malaysia. The leaves (PIIUM 
0238-2) were authenticated by Herbarium, Kulliyah of 
Pharmacy, IIUM. These collected leaves were separated 
from the stems, washed thoroughly and dried in an oven 
at 50°C for three days. The dried sample was grinded 
to powder. The dried powdered leaves (500 g) were 
sequentially extracted with hexane and chloroform (Merck, 
Germany), respectively. 50 g of powdered CN leaves were 
soaked in 300 ml of hexane and were incubated in the 
water bath at around 60°C for 8 hours. The mixture was 
then filtered. The leaves remnants were next extracted 
with chloroform by using Soxhlet extraction for two days. 
The chloroform extract was concentrated by using rotary 
evaporator at 60°C, which were later fractionated using 
column chromatography. The concentrated crude extract 
was dried in the fume hood for several days until semi-solid 
extract was obtained.
BIOASSAY GUIDED FRACTIONATION
The CN extract was subjected to column chromatography 
on silica gel column (Merck, Germany). The column 
was eluted successively with hexane-ethyl acetate (1:1), 
ethyl acetate, chloroform-ethanol (1:1), and ethanol. 
Major fractions were collected by monitoring with TLC 
(Chloroform-methanol 1:1).These entire fractions were 
examined for cytotoxicity by MTT assay method. 
Fraction with the lowest IC50 value was selected for 
further isolation. Further isolation was conducted to identify 
major compound content in the most active fraction. This 
fraction was further chromatographed on a silica gel 60 and 
eluted with acetonitrile-methanol (20:80). Later, a portion 
of each fraction was separated by preparative thin-layer 
chromatography (chloroform-methanol 2:8). 
CELL CULTURE
One human cancer line and two normal human cell 
lines were purchased from the American Type Culture 
Collection (ATCC, USA). They were; 1) Human cervical 
cancer (HeLA cell); 2) normal subcutaneous connective 
tissue (L929 cell) 3) Normal embryo fibroblast cell (NIH 
3T3). Each cells were cultured in Dulbecco’s modified 
Eagle medium (Gibco, USA) supplemented with 5% fetal 
bovine serum (Gibco, USA) 100 units/ml penicillin and 100 
μg/mL streptomycin (Gibco, USA) at 37°C in a humidified 
atmosphere containing 5% CO2. Phosphate buffered saline 
(Merck, Germany) was used for washing and 0.025% 
trypsin-EDTA (Gibco, USA) was used to detach the adherent 
cell from the flask. 
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PREPARATION OF EXTRACT
CN extract was diluted in DMSO (Nacalai Tesque, Japan) 
to various concentrations (10, 5, 2.5, 1.25, 0.625, 0.3125, 
0.155625, 0.078125, 0.0390625 and 0.01953125 µg/mL). 
Two μL of each extract was introduced to the cell culture 
at 96 well plates (Eppendorf, Germany) after cells reached 
80% confluency.
MTT ASSAY PROTOCOL
Culture flasks with 80-90% confluent cells were chosen to 
be plating into a 96-well plate. Before seeding, detached 
cells were counted by using cell counter (Invitrogen, USA). 
Cells were then seeded for 24 hours prior to treatment in a 
96-well plate. The concentration of live cells was 5 × 104 
cell/well in 100 µl of medium. After overnight incubation, 
the old medium was discarded before the addition of 200 
μl fresh culture medium. The CN fractions and tamoxifen 
(Sigma-Aldrich, USA) the positive control, was dissolved 
in DMSO. A range from 0.04 to 100 μg/ml was added to 
the cells by following two-fold serial dilution (Zakaria 
et al. 2009; Zazali et al. 2013). Each well received 2 μl 
from the serial dilution. Negative control cultures were 
supplied with only DMSO at the same concentration of 
solvent alone. The final concentration of DMSO was 1% 
(v/v) or less and this must be standardized throughout 
all wells. Each concentration of the extract was assayed 
in triplicate. Cells were incubated at 37°C and 5% CO2. 
The assay was terminated at 72 hours and the number of 
surviving cells was determined by MTT assay. At the end 
of the incubation, 50 μl of MTT reagent (Merck, Germany) 
(2 mg/ml MTT in serum free culture medium) was added 
to each well. The plate was then incubated for 4 hours. 
MTT solution was removed and purple formazan crystal 
formed at the bottom of the wells was dissolved with 200 
μl DMSO and was gently mixed on a shaker (Heidolph, UK) 
for 20 minutes. The absorbance at 570 nm was recorded 
on a spectrophotometric plate reader (Biorad Model 680, 
USA). The proportion of surviving cells was calculated as 
(absorbance of extract)/ (absorbance of control) × 100%. 
Dose-response curves graph were ploted to obtain the 
IC50 values.
HOECHST 33258 NUCLEAR STAINING ASSAY
Nuclear staining with Hoechst 33258 was performed as 
described by Zakaria et al. (2009) with minor modification. 
Hoechst 33258 is used to visualize the apoptosis event 
including apoptotic bodies and nuclear changes when the 
dye binds to the DNA producing fluorescence blue color 
under fluorescence microscope. Firstly, HeLA cells were 
seeded in petri dishes (Thermofisher, USA) at 5 × 104 cells/
ml that consist of sterilize microscope Poly-Lysine adhesion 
slide (Thermofisher, USA) and were incubated under 
humidified 5% CO2 atmosphere at 37°C overnight. The next 
day, cells were treated with IC50 of the most active fraction 
and IC50 of tamoxifen as a positive control, for 24 hour, 48 
hour and 72 hour. Negative control only received DMSO less 
than 1% of final concentration. At each incubation time, the 
slides were washed three times with PBS then left to dry in 
the Biological Safety Cabinet (ERLA, Malaysia). Then, the 
slides were fixed with cold ethanol for 2 hours at 4°C. After 
that, all slides were incubated with 30 µg/mL Hoeshct 33258 
(Invitrogen, USA) at room temperature in a dark condition. 
Nuclear morphology of each different time of treatment 
was examined under fluorescent microscope at 40X 
magnification (Imaging Source Europe GmbH, Bremen, 
Germany). Direct light was avoided when examining the 
slides. For long term storage, the slides were wrap with 
aluminum foil and kept in 4°C. 
CELL CYCLE ANALYSIS
Determination of cell cycle was performed as reported by 
Zakaria et al. (2009) with minor modification. Cells were 
cultured in 25 cm2 culture flasks under humidified 5% CO2 
atmosphere at 37°C. The seeding density was 5 × 104 cell/
ml. Cells were incubated overnight before the treatment 
with the most active CN fraction. Tamoxifen and DMSO 
were used as a positive and negative control respectively. 
When HeLA cell was about 70-80% confluent, the cells 
were treated with IC50 of the most active CN fraction and 
IC50 of tamoxifen. After incubation at 24 hours, 48 hours 
and 72 hours, the medium was decanted into 15mL falcon 
tube (BD, USA) in order to collect apoptotic floating cells. 
Cells were harvested by trypsinization with trypsin EDTA 
solution, and centrifuged at 1500 rpm for 5 minutes. The 
pelleted cells were then fixed with ice-cold 70% ethanol 
via gentle vortexing (ERLA, Malaysia) for 1 hour at 4°C. 
After that, the cells were centrifuged (2000 rpm, 4°C) and 
the pellet was re-suspended with 1 ml 1% Triton X-100 
(Thermofisher, USA) in PBS and 100 μl of 1 mg/ml RNase 
A (Amresco, USA) was added. The solution was incubated 
for 30 minutes at 37°C. After that, cells were stained with 
100 μl of 10 μg/ml Propidium Iodide solution (Merck, 
Germany) in staining buffer (1% Triton-X 100 in PBS) in 
dark. Stained cells were incubated at room temperature 
for 30 minutes. Then, the samples were put on ice and 
300 μl of staining buffer was added prior to analysis with 
Flow Cytometry (FCM) (Beckman-Coulter, USA). Samples 
were kept on ice and protected against light until the FCM 
analysis (within 24 hour). 
LCMS ANALYSIS
Characteristic of the compounds present in the most active 
fraction was further investigated. This fraction for analysis 
was prepared at concentration of 10 mg/ml with methanol 
(Merck, Germany). The sample was sent to Monash 
University for LCMS analysis. The compound detection was 
done by Agilent-1290-Infinity-system coupled to Agilent-
6520 Accurate-Mass Q-TOF mass-spectrometer with dual 
ESI. The MS parameter was set to MS mode with negative 
and positive polarity programmed. 
JSKM16(2) 6.indd   41 17/05/2018   3:37:40 PM
42
STATISTICAL ANALYSIS
The data was presented as mean ± S.D. of three independent 
experiments. The statistical significances of data obtained 
were calculated and evaluated using two ways analysis 
of variance (two-way ANOVA) with Tukey’s multiple 
comparison tests or Student’s paired t test. Null hypothesis 
rejection was set for significance level of 0.05 (p < 0.05). 
The results were considered significance, if *p < 0.05, **p 
< 0.01, ***p < 0.00.1.
RESULTS
FRACTIONATION OF CN BY COLUMN CHROMATOGRAPHY
A total of 132 fractions were collected. These fractions 
were combined with similar TLC profile pattern resulting 
in total of 16 fractions; ethyl acetate: hexane (12 fractions), 
ethyl acetate (2), ethanol: chloroform (2 fractions) and 
ethanol (no fractions).
CYTOTOXICITY OF CN FRACTIONS
The IC50 is defined as a reduction of 50% in absorbance 
compared to the control values (Noriaki et al. 1988). The 
lowest value of IC50 from the 16 fractions showed that it is the 
most active fractions towards cancer cells. Preliminary study 
showed that CN extract inhibited cancer cell proliferation and 
was potent against cervical cancer cell line, HeLA. HeLA 
cell were then selected for further research studies.
Sixteen different fractions were subjected to 
cytotoxicity assay to obtain the IC50 value. Throughout 
this study, F11 from the elution of ethyl acetate: hexane 
has the lowest value of IC50 compared to the other fractions 
at 27 ± 2.6 µg/mL. IC50 values of the other fractions were, 
F1 (70 ± 4.5) µg/mL, F2 (89 ± 3.1) µg/mL, F3 (80 ± 7.1)
µg/mL, F6 (60 ± 7.6) µg/mL, F12 (70 ± 5.1) µg/mL, F14 
(76 ± 4.6) µg/mL, and F16 (34 ± 2.6) µg/ml. While as for 
the other fractions, F4, F5, F7, F8, F9, F10, F13 and F15, 
could not be extrapolated since none of the concentration of 
these fraction was able to reduce the proliferation activity to 
50%. IC50 values exceeding 100 µg/ml were considered not 
detected. The IC50 values of all fractions are shown in Table 
1. F11 has the lowest IC50 value; therefore this fraction was 
used for treatment in the subsequent experiment towards 
normal cell lines, NIH 3T3 and L929. IC50 values for F11 
were of 70 ± 4.0 µg/mL against NIH 3T3 and 45 ± 1.5 µg/
mL against L929.
The positive control, tamoxifen gave IC50 value of 1µg/
mL against L929 cell lines and 1.3 µg/mL against NIH T3T. 
This showed that tamoxifen is toxic for both cancerous and 
non-cancerous cells. Table 2 shows the IC50 value of F11 
and tamoxifen against cancer and normal cell line.
MORPPHOLOGY OF APOPTOSIS BY HOECHST STAINING
When cells undergo apoptosis, Hoesct 33258 dye will 
stain the nuclei of the cell and produce bright blue color. 
Nuclei of the living cells, will only produce homogeneous 
and weak fluorescence of blue color (Mingxin et al. 2006). 
Based on Figure 1, untreated HeLA cell remained unstained 
at 24 and 48 hours, but started to produce fluorescence blue 
color at 72 hours, indicating it was beginning to undergo 
apoptosis. At 72 hours, treated cell with F11 exhibited 
brighter blue emission light in than the control untreated 
cell. In untreated cell, no condensation of chromatin was 
detected all time point indicating that the cell was not 
undergoing apoptosis. As early as 24 hours, cell treated 
with F11displayed condensation of chromatin in the nuclei. 
At 48 and 72 hours after treatment, the condensation of 
the chromatin and the structure of the apoptotic bodies 
formed can be seen clearly. These are the characteristics 
of apoptotic cell.
Tamoxifen treated cell showed apoptosis morphology 
and presence of DNA fragmentation at 24 hours of 
treatment. At 48 and 72 hours, the apoptotic bodies formed 
and the nuclear fragmentation and condensation were more 
evident. By comparing cell treated with F11 and tamoxifen, 
both treated cells displayed the same characteristics of 
apoptotic events, indicating that the observations obtained 
from F11 treated cell are acceptable. It clearly showed that 
F11 induced apoptosis in HeLA cell. The apoptosis event 
of HeLA cell treated with F11 was further investigate to 
analyze the cell cycle arrest.
TABLE 1. The IC50 values of CN fractions on HeLA cell
 Fractions of CN extract IC50/µgmL
–1
 F1 70 ± 4.5
 F2 89 ± 3.1*
 F3 80 ± 7.1*
 F4 >100
 F5 >100
 F6 60 ± 7.6*
 F7 >100
 F8 >100
 F9 >100
 F10 >100
 F11 27 ± 2.6***
 F12 70 ± 5.1**
 F13 >100
 F14 76 ± 4.6*
 F15 >100
 F16 34 ± 2.6*
 Positive control, Tamoxifen 3.3 ± 1.51
EFFECT OF F11 ON CELL CYCLE PROGRESSION
Since F11 induced cell death towards HeLA cells happened 
via apoptosis, the effect of F11 towards DNA content in 
the cell cycle was also examined. The relative untreated 
and F11-treated HeLA cell was presented at three distinct 
stages that are G0/G1, S and G2/M phases. These phases are 
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represented in the interphase stage of cell cycle. Based on 
the results (Figure 2), there were no significance changes 
in DNA content in each phase of the cell under normal 
conditions (untreated). The expected pattern showed for 
continuing cell growth as for region at G1 phase is the 
highest peak and the lowest peak is at G2/M phase. At G1 
phase, the DNA content were 41.54 ± 0.32%, 54.83 ± 1.14% 
and 53.35 ± 1.35% at 24, 48 and 72 hours respectively. 
During S phase, the DNA content were 41.27 ± 1.14% at 24 
hours, 28.39 ± 1.81% at 48 hours and 31.26 ± 0.61% at 72 
hours. For G2/M phase, throughout 24, 48 and 72 hours, it 
TABLE 2. The IC50 values of F11 and tamoxifen against cancer 
and normal cell line. The value are represented as mean ± S.D. 
with **p < 0.001 and ***p < 0.0001 were taken as significantly 
different from tamoxifen, positive control
  Cell line  IC50/µ gmL
–1
  F11 Tamoxifen
Cancer cell     HeLA Cell 27 ± 2.6*** 3.3 ± 1.5
Non-cancerous cell    L929 45 ± 1.5** 1.0 ± 0.006
 NIH 3T3 70 ± 4.0** 1.3 ± 0.1
(a)
(d)
(g)
(b)
(e)
(h)
(c)
(f)
(i)
FIGURE 1. Nuclear staining of HeLA cells with Hoescht stain 33258. Cell were left untreated (a, b and c), treated with 27 µg/mL of 
F11 (d, e, f) and 3.3 µg/mL with tamoxifen for 24, 48 and 72 hours (g, h, i) respectively. Arrow indicates (1) unstained  
(2) bright fluorescence (3) apoptotic body (4) nuclear condensation. Magnification: 40×
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remains the lowest peak, which were 17.19 ± 1.35%, 16.78 
± 0.86% and 15.48 ± 1.22% respectively. Since the pattern 
of cell cycle distribution was almost the same throughout 
all time point, there is no cell cycle arrest happened for 
untreated HeLA cell.
In F11-treated HeLA cells, the profile of the cell cycle 
changed upon treatment. At 24 hours after treatment, 
DNA content at G1 phase increased up to 49.47 ± 7.71%, 
decreased to 34.43 ± 8.9% in S phase and declined to 15.6 
± 3.8% in the G2/M phase. After 48 hours of treatment, the 
DNA content at G1 phase was 48.42 ± 8.05%, which was 
similar with the DNA content at G1 phase of the 24 hours of 
treatment. The DNA content was slightly decreased to 38.92 
± 5.14% at S phase, and further declining to 12.64 ± 3.14% 
at G2/M phase. At 72 hours of treatment, the DNA content at 
G1 phase continued to increase up to 74.91 ± 6.22% while 
in S phase, its dramatically decreased to 15.48 ± 6.48% and 
at G2/M phase, the DNA content declined to 9.25 ± 0.53%. 
These results showed that the proliferation of HeLA cells 
treated with F11 was inhibited during G1 phase. This is 
because there was increment of DNA content at this phase 
and decrement during S phase and G2/M phase.
Cells treated with tamoxifen treatment for positive 
control, the growth peaks were dramatically increased at 
G1 phase throughout 24 to 72 hours with the DNA content 
percentage were 44.36 ± 1.23% for 24 hours, 60.28 ± 
0.66% at 48 hours and 82.44 ± 5.01% at 72 hours. The DNA 
content during S phase decreased to 41.53 ± 0.84% at 24 
hours, 25.98 ± 0.71% at 48 hours and 11.72 ± 4.9% at 72 
hours. During G2/M phase, the DNA content declined to 
14.11 ± 1.61% at 24 hours and 13.75 ± 0.16% at 48 hours. 
The major declined on G2/M occurred at 72 hours with the 
percentage of 6.28 ± 1.78%. This indicate that the cycle 
arrest for tamoxifen-treated HeLA cell cycle arrest at the G1 
phase. Figure 2 showed the results of cell cycle distribution 
by flow cytometry displayed in DNA histograms.
CHARACTERIZATION OF F11
F11 was subjected to LCMS analysis in order to characterize 
the active anticancer compound present. Four major 
peaks from negative polarity and five major peaks from 
positive polarity in chromatogram were selected. These 
major peaks are believed responsible for the anticancer 
effect. Major known constituents in F11 at the negative 
polarity are 19-Oxo-all-trans-retinoic acid (3.76%), 
(2S)-2-({2-[1-(propan-2-yl)-1H-1,2,4-triazol-5-yl]-5,6-
dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl}oxy)
propanamide (2.19%), pregnenolone sulfate (1.83%) and 
9,13-di-cis-retinoic acid (1.72%). There was one unknown 
compound, C21H30O6S (1.61%), among the major peaks 
that did not match with the METLIN database (Table 3). 
As for positive polarity, the known constituents for major 
peaks are tetradecaethyleneglycol (4.59%), Elaidamide 
(9.63%) and 19-oxo-all-trans-retinoic acid (2.45%). 
There were three unknown major compounds that did 
not have any match with the library, METLIN database. 
The compounds are C23H42N4O8 (4.71%), C25H46N4O9 
(4.95%) and C27H50N4O10 (5.26%) (Table 4). The LCMS 
chromatograms of the negative and positive mode are as 
shown in the Figure 3 and Figure 4 respectively. These 
major compounds were selected with db score higher than 
90%, which indicated that they have the highest similarity 
with the compounds on the database.
TABLE 3. List of constituents (major peaks) identified by LCMS scan on F11 for negative polarity
No. Formula Compound Retention Mass % of  
   time  volume
1 C20H26O3 19-Oxo-all-trans-retinoic acid 16.864 314.1894 3.76
2 C19H22N6O3 (2S)-2-({2-[1-(propan-2-yl)-1H-1,2,4-triazol-5-yl]-5,6- 16.88 382.176 2.19
  dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl}oxy)propanamide
3 C21H30O6 Unknown 16.88 410.1769 1.61
4 C21H32O5 pregnenolone sulfate 18.972 396.1972 1.83
5 C20H28O2 9,13-di-cis-retinoic acid 18.972 300.209 1.72
TABLE 4. List of constituents (major peaks) identified by LCMS scan on F11 for positive polarity
No. Formula Compound Retention Mass % of  
   time  volume
1 C23H42N4O8 Unknown 9.231 502.3009 4.71
2 C25H46N4O9 Unknown 9.359 546.3266 4.95
3 C27H50N4O10 Unknown 9.488 590.3528 5.26
4 C28H58O15 tetradecaethyleneglycol 9.585 634.3784 4.59
5 C20H26O3 19-oxo-all-trans-retinoic acid 16.954 314.1968 2.45
6 C18H35NO Elaidamide 21.058 281.2731 9.63
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FIGURE 2. The histogram profile of cell cycle progression detected by flowcytometry analysis in untreated (a – c) HeLA cell 
(negative control), F11-treated (d – f) HeLA cell and Tamo-treated (g – i) HeLA cells (positive control) for 24 hours  
(column 1), 48 hours (column 2) and 72 hours (column 3) 
Indication:
Debris G1 S G2/M
(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
CHARACTERIZATION OF ISOLATED F11
F11 was further isolated by column chromatography. 
There were four major fractions collected. These four 
fractions were analyzed using LCMS for characterization 
and determination of major compound. These four 
fractions were namely F11-a, F11-b, F11-c and F11-d. 
The characterization was conducted to confirm whether 
the active anticancer compound in F11 could be selected 
as the major compound in CN. The major compound for 
all isolated fraction, F11-a, F11-b, F11-c and F11-d were 
summarized in Table 5 to Table 12. Each of the fractions 
shows the compound for negative and positive polarity.
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FIGURE 3. LCMS chromatogram of negative mode for F11
FIGURE 4. LCMS chromatogram of positive mode for F11
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TABLE 5. List of constituents (major peaks) identified by LCMS scan on F1 for negative polarity
No. Formula Compound Retention Mass    
   time
1 C33H22N6O9S3 Unknown 16.279 742.0603
2 C21H26O3 2-Methoxy-17a-ethynylestradiol 17.852 326.1894
3 C21H26O3  Unknown 18.286 326.1913
4 C14H30O4S Tetradecyl sulfate 18.608 294.1851
5 C20H30Cl3N7O Unknown 20.227 489.1582
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TABLE 6. List of constituents (major peaks) identified by LCMS 
scan on F1 for positive polarity
No Formula Compound Retention Time Mass
1 C28H8N6O3 Unknown 8.239 476.0671
2 C25H20N12S Unknown 8.407 520.1654
3 C20H32N14O6 Unknown 8.554 564.2633
4 C20H40N20O3 Unknown 8.685 608.3599
TABLE 7. List of constituents (major peaks) identified by LCMS 
scan on F2 for negative polarity
No Formula Compound Retention Mass
    Time
1 C20H26O3 19-Oxo-all-retinoic acid 15.421 14.1876
2 C17H28O3S Unknown 17.038 312.176 
3 C14H21NO3 Unknown 17.124 251.1518
4 C18H30O3S Unknown 18.279 326.192
5 C14H30O4S Tetradecyl sulfate 18.528 294.1865
TABLE 8. List of constituents (major peaks) identified by LCMS 
scan on F2 for positive polarity
No Formula Compound Retention Mass
   Time
1 C10H18N2O2 Slaframine 1.962 198.1368
2 C5H9NO δ-Valerolactam 1.962 99.0686
3 C25H50N10O9 Unknown 8.827 634.3766
4 C20H26O3 19-oxo-all-trans- 15.422 314.1881
  retinoic acid 
5 C38H30ClN3O4 Unknown 20.685 627.1929
TABLE 9. List of constituents (major peaks) identified by LCMS 
scan on F3 for negative polarity
No Formula Compound Retention Mass
   Time
1 C12H26O4S Lauryl hydrogen sulfate 16.009 266.1544
2 C18H30O3S Unknown 18.317 326.1914
3 C14H30O4S Tetradecyl sulfate 18.557 294.186
4 C19H32O3S Unknown 19.649 340.207
5 C20H26N4O Lisuride 19.846 338.2123
TABLE 10. List of constituents (major peaks) identified by LCMS scan on F3 for positive polarity
No Formula Compound Retention time Mass
1 C6H4Cl2N2O Unknown 0.585 189.9714
2 C5H9NO δ-Valerolactam 1.958 99.0678
3 C24H50O13 Unknown 8.557 502.2983
4 C12H10O2S Cis-1,2-Dihydroxy-1,2- dihydrodibenzothiophene 12.843 218.0405
5 C38H30ClN3O4 Unknown 20.684 627.1924
TABLE 11. List of constituents (major peaks) identified by LCMS scan on F4 for negative polarity
No Formula Compound Retention time Mass
1 C13H18O3 Unknown 12.426 222.1271
2 C16H20N6O Unknown 17.522 312.1709
3 C21H26O3 2-Methoxy-17a-ethynylestradiol 18.309 326.1863
4 C21H24O5 8-Prenylafzelechin 5-methyl ether 20.268 356.162
TABLE 12. List of constituents (major peaks) identified by LCMS scan on F4 for positive polarity
No Formula Compound Retention time Mass
1 C5H9NO δ-Valerolactam 1.959 99.0685
2 C24H50O13 Unknown 8.556 546.3252
3 C12H10O2S Cis-1,2-Dihydroxy-1,2- dihydrodibenzothiophene 12.834 180.1146
4 C20H26O3 19-oxo-all-trans-retinoic acid 15.421 314.1885
5 C38H30ClN3O4 Unknown 20.684 627.1924
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DISCUSSION
Normally, chemotherapy or neoadjuvant chemotherapy 
is always the first chosen strategy to treat cancer patients. 
However, the use of chemotherapy is limited due to the 
lack of selectivity and too many side effects (Sultana 
et al. 2003). Therefore, the researchers need to explore 
more potent antitumor drugs with lesser or minimal 
side effect as new sources of pharmacologically active 
compounds especially from natural sources (Shi et al. 
2006). According to the study by Yong Keong Yok (2013), 
the value of IC50 obtained from the CN chloroform extract 
was 36.31 µl/mg against HeLA cell. However, fraction 
of CN F11, exhibited lower value of IC50 against HeLA 
cell which is 27 µg/mL. This is because of the pure 
substance existed in the isolated compound as compared 
to the crude extract, which consists of various amounts of 
active constituents (Colegate & Molyneux 2007). A study 
from Rodrigues et al. (2011) also showed that the isolated 
compound exhibited stronger cytotoxicity compared to 
the crude extract due to the presence of other compound 
involved in antiproliferative activity.
Meanwhile, the anti-proliferative activity for normal 
cell lines, normal fibroblast NIH 3T3 and L929 normal 
connective cells, were also tested to see whether F11 is 
toxic towards them. There were no effects of F11 towards 
to these cells as compared to HeLA cell. This was supported 
with the finding by Yong et al. (2013) which showed that the 
normal cell used for this study was human umbilical veins 
endothelial cell (HUVECs) exhibited lowest percentage of 
inhibition as compared to other cancer cells when treated 
with CN extract. If the value of IC50 is more than 99µg/ml 
against the normal cell, it is considered as no inhibitory 
effect on cells (Zazali et al. 2013). According to the US NCI 
plant-screening program, IC50 of a pure compound less than 
4 µg/ml is considered to have in vitro cytotoxic activity 
(Zakaria et al. 2009). Since the IC50 value of F11 towards 
normal cell is more than 4 µg/mL, it does not affect the 
growth of normal cell. The selective cytotoxicity is may 
be due to the difference of the genetics, biochemical and 
molecular of the mitochondria in cancer and normal cell 
line (Mclanchan et al. 2005). The metabolic rates of cancer 
cells are higher compared to non-malignant cells, which 
may be related to the changes in the mitochondrial TCA 
cycle (Piva & McEvoy-Bowe 1998). This will make the 
tumor mitochondria to be unstable (Liu et al. 2007) and 
thus, making these cells more sensitive to F11.
One of the ways to determine the potential anticancer 
of drugs or extracts is the ability to induce apoptosis in 
cancer cells. It is important to ensure that the drugs or 
extract induce apoptosis in cancer cells because apoptosis 
eliminates cancer cells while not affecting normal cells and 
its surrounding tissues (Ashkezanki 2008). In this study, 
the morphology of the cells was determined by fluorescent 
microscope. The AT rich regions of double stranded DNA 
showed strong fluorescence because of the binding to 
Hoechst dye (Zakaria et al. 2009). The blue fluorescence 
Hoechst 333248 was able to diffuse into the membrane 
of HeLA cells and stained their membrane. In this study, 
treatment with IC50 value of F11 induced apoptosis in HeLA 
cells. Cell treated with F11 at 24 hours, started to show 
nuclear chromatin condensation, cytoplasmic vacuolation, 
nuclear fragmentation and presence of apoptotic bodies 
which in line with findings of previous studies. (Zakaria 
et al. 2009; Rahman et al. 2013; Beedessee et al. 2012). The 
DNA fragmentation showed at 24 hours of treatment is the 
early event of apoptosis that represent irreversible process 
to cell death (Allen et al. 1997). Increase in the nuclear 
membrane permeability of the apoptotic cell makes the 
fluorescence dye more intense which indicates chromatin 
condensation and nuclear fragmentation (Abdullah et al. 
2010). This observation was also observed in tamoxifen-
treated HeLA cells at all time point. This observation 
proved that the HeLA cells treated with F11 undewent 
apoptotic pathway.
Determination of cell cycle distribution in cells treated 
with F11 was analyzed using flow cytometer via the 
measurement of DNA content. Upon treatment with F11, 
the population at G1 phase increased but the cell growth 
was inhibited when entering S phase because of the stress 
or DNA damage that was triggered by F11. Thus, there is 
no growth occurred in G2/M phase. The checkpoint arrest 
at G1/S phase is important to avoid the replication of the 
cell and to allow damaged DNA to be repaired (Vermeulen 
et al. 2003). As for this study, the growth of the cell arrest 
at G1 checkpoint after 72 hours showed that cell division 
has stopped completely since DNA synthesis in HeLA cell 
cannot be occur. The cell cycle distribution for Tamoxifen-
treated HeLA cells showed similar pattern to the F11-
treated HeLA cells.
Identification of active compound present in F11 was 
analyzed by using LCMS. LCMS is one of the powerful 
analytical tools for identification of organic compounds 
as it provides molecular weight and chemical structure 
information. The major peaks showed in the chromatogram 
are believed to contribute to the anticancer effect. The 
constituents in F11 that has been detected by LCMS as 
negative polarity are 19-Oxo-all-trans-retinoic acid, 
(2S)-2-({2-[1-(propan-2-yl)-1H-1,2,4-triazol-5-yl]-5,6-
dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl}oxy)
propanamide, pregnenolone sulfate and 9,13-di-cis-retinoic 
acid and at for positive polarity, the major constituent are 
tetradecaethyleneglycol and Elaidamide. Out of all major 
constituents present in F11, only 19-oxo-all-trans-retinoic 
acid and 9,13-di-cis-retinoic acid exhibit anticancer effect 
based on previous studies (Adamson 1996; Uchida et al. 
2001; Akira et al. 1993). So, it is assumed that 19-oxo-
all-retinoic acid is the active anticancer compound and to 
confirm that this is the major compound, double column 
chromatography was conducted on F11. The results showed 
that 19-oxo-all-trans-retinoic acid was present in F11-b (in 
negative and positive mode) and F11-d (positive mode) and 
it was detected at the same retention time as F11. Thus, 
19-oxo-tran-retinoic acid is confirmed to be as one of the 
JSKM16(2) 6.indd   48 17/05/2018   3:37:45 PM
49
major compounds. In this study, the active compound 
that is responsible for the anticancer effect is 19-oxo-all-
trans-retinoic acid since the volume of all-trans-retinoic 
acid in F11 is higher than 9,13-di-cis-retinoic acid and 
this compound was also detected in the isolated fraction, 
which prove this is the major compound. 
For the unknown compound, this new compound 
has not been established and known yet since it cannot 
be identified in the database. However, it is assumed that 
C21H3O6S is a conjugate acid since the compound is similar 
with prenenolone acid. As for C23H42N4O8, C25H46N4O9 
and C27H50N4O10, it is assumed to be alkaloid since the 
chemical compound contain basic nitrogen atom. These 
compounds need to be isolated from F11in order to obtain 
pure compound and then analyze by NMR to identify the 
name and structure of the compound. 
CONCLUSION
Fraction 11 (F11) from the elution of ethyl acetate: hexane 
inhibited cells growth at G1 phase checkpoint indicating 
that the cell division has stop at this point. The mechanism 
of cell death induce by F11 was via apoptosis. The 
active compound believed to contribute to the anticancer 
properties is 19-oxo-all-trans-retinoic acid. This can be 
concluded that the active compound of CN, 19-oxo-all-
trans-retinoic acid, demonstrates promising anticancer 
effect by inducing apoptosis in HeLA cells. 
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